Covid-19 creates uncertainty for Zealand Pharma drug against short bowel syndrome

Zealand Pharma's clinical development is running smoothly and the firm has sent a new drug candidate to clinic. Reversely, the resurgence of the Covid-19 pandemic has caused uncertainty regarding the time schedule for the firm's phase III drug Glepaglutide.

Zealand Pharma's CEO Emanuel Dulac. | Photo: Stine Bidstrup/ERH

As a biotech firm, Zealand Pharma's first priority during Covid-19 has been to ensure that its research and development program could continue with as few alterations as possible.

This was, to some extent, successful, but Zealand Pharma still had some minor setbacks.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs